From General-Purpose to Disease-Specific Features: Aligning LLM Embeddings on a Disease-Specific Biomedical Knowledge Graph for Drug Repurposing.
Introduces CLEAR, a method that aligns LLM embeddings with a disease-specific knowledge graph to improve computational drug-repurposing predictions for ADRD, including Parkinson disease–related dementia, reporting up to 30% performance gains.
What the AI sees
Introduces CLEAR, a method that aligns LLM embeddings with a disease-specific knowledge graph to improve computational drug-repurposing predictions for ADRD, including Parkinson disease–related dementia, reporting up to 30% performance gains.
Research significance
Offers a scalable, context-grounded computational approach to prioritize FDA-approved repurposing candidates for Parkinson-related dementia and other ADRD in data-sparse settings, potentially accelerating translational follow-up despite lacking in vitro/in vivo validation.
Source abstract
Identifying new therapeutic uses for existing drugs is a major challenge in biomedicine, especially for complex neurodegenerative conditions such as Alzheimer disease and related dementias (ADRD), where treatment options remain limited and relevant data are often sparse, heterogeneous, and difficult to integrate. Although general-purpose Large Language Model (LLM) embeddings encode rich semantic information, they often lack the task-specific biomedical context needed for inference tasks such as computational drug repurposing. We introduce Contextualizing LLM Embeddings via Attention-based gRaph learning (CLEAR), a multimodal representation-fusion framework that aligns LLM embeddings with the topological structure of a context-specific Knowledge Graph (KG). Across five benchmark datasets, CLEAR achieved state-of-the-art results, improving predictive performance (e.g., F1 score) by up to 30% over prior methods. We further applied CLEAR to identify FDA-approved drugs with potential for repurposing for ADRD, including Parkinson disease-related dementia and Lewy Body dementia. CLEAR learned a biologically coherent embedding space, prioritized leading ADRD drug candidates, and accurately summarized known therapeutic relationships for FDA-approved Alzheimer disease drugs. Overall, CLEAR shows that grounding biomedical LLM embeddings with context-specific KG signals can improve drug repurposing in data-sparse, real-world settings. GitHub: https://github.com/bozdaglab/CLEAR.